Infectious Diseases

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses vaccine hesitancy and hopes to increase vaccination for preventable diseases in 2024.

The unprecedented demand for nirsevimab-alip has resulted in a dramatic uptake in production of this RSV vaccine.

In the second installment of RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

Steven Selbst, MD, provides a quick update on what he has noticed in his hospital when it comes to RSV-associated emergency department visits and how they compare to this time last year, during the "tripledemic." This interview was conducted at the 2023 American Academy of Pediatrics National Conference and Exhibition in Washington DC.

Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.

A sneak peek at some of the most exciting sessions at this year's American Academy of Pediatrics national conference.

Parents who reported the stigmatizing belief “My child is not having sex” were much more likely to rely on health care providers as a source of information than parents who did not report this belief.

For this highly infectious disease, a thoughtful and comprehensive approach to care and treatment are a necessity.

At IDWeek 2023, a presentation sharing the latest news in RSV vaccines.

At IDWeek 2023, a session on how increased rates of the HPV vaccine have resulted in a decline in certain conditions and disease states.

At IDWeek 2023, a presentation on the challenges to the diagnosis and management of VAIs in children.

At IDWeek 2023, updates on CLABSIs in the pediatric population.

At IDWeek 2023, a presenter shares his own studies on the impact of viral effects after infection.

At IDWeek 2023, a presenter discusses the future of infection prevention from organ transplants in children.

At IDWeek 2023, several authors share a study on mother-infant pairs, evaluating for differences in rates of influenza infections in infants.

At IDWeek 2023, a discussion of the best end of therapy for Gram-negative neonatal meningitis.

At IDWeek 2023, a session on TB, which remains a formidable foe in global pediatric health.

At IDWeek 2023, a presentation on the emotional and financial cost of climate change, and what clinicians can do right now to help.

At ID Week 2023, 2 health care providers argue the pros and cons of treatments for newborns with bacteremic UTIs.

At IDWeek 2023, a White House expert on Mpox discusses initial reactions to the outbreak, vaccination rates, and where we need to do better in combatting this infectious disease.

At IDWeek 2023, a presentation on the latest recommendations for screening and management of hepatitis C in the pediatric population.

At a plenary session at IDWeek 2023, the benefits and challenges of using AI in treating infectious diseases was discussed.

New immunizations for RSV are making this respiratory infection preventable in ways it never was before. Here is the latest news on recent approvals and future outlooks.